These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
11. Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review. Popescu A; Haidar A; Anghel RM Rom J Intern Med; 2018 Jun; 56(2):122-126. PubMed ID: 29168975 [TBL] [Abstract][Full Text] [Related]
12. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064 [TBL] [Abstract][Full Text] [Related]
13. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103 [TBL] [Abstract][Full Text] [Related]
14. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. Queirolo P; Spagnolo F Cancer Metastasis Rev; 2017 Mar; 36(1):35-42. PubMed ID: 28299583 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408 [TBL] [Abstract][Full Text] [Related]
17. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. Kim DW; Barcena E; Mehta UN; Rohlfs ML; Kumar AJ; Penas-Prado M; Kim KB BMC Cancer; 2015 May; 15():400. PubMed ID: 25962795 [TBL] [Abstract][Full Text] [Related]
18. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777 [TBL] [Abstract][Full Text] [Related]
19. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]